Development of [⁸⁹Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer.

ABSTRACT:

Background

Amivantamab is a novel bispecific antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (HGFR/c-MET) that are overexpressed in several types of cancer including triple-negative breast cancer (TNBC). Targeting both receptors simultaneously can overcome resistance to mono-targeted therapy. The purpose of this study is to develop ⁸⁹Zr-labeled amivantamab as a potential companion diagnostic imaging agent to amivantamab therapy using various preclinical models of TNBC for evaluation.

Methods

Amivantamab was conjugated to desferrioxamine (DFO) and radiolabeled with ⁸⁹Zr to obtain [⁸⁹Zr]ZrDFO-amivantamab. Binding of the bispecific [⁸⁹Zr]ZrDFO-amivantamab as we

SUBMITTER: Cavaliere A 

PROVIDER: S-EPMC7855369 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature